# An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

> **NCT01571583** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 74 (actual)

## Conditions studied

- Chronic Hepatitis C Virus (HCV) Infection

## Interventions

- **DRUG:** Telaprevir
- **DRUG:** Pegylated interferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01571583
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-07
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2016-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01571583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01571583, "An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01571583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*